Series
Most Recent Segment
What This Means
Featuring American Resources
December 8, 2025
Mark Jensen, Executive Chairman of American Resources and CEO of ReElement Technologies, and Jacob Clayton, CEO of SAGINT Inc., discuss the strategic collaboration between the companies to implement blockchain-based tokenization for global critical mineral traceability and transparency.
What This Means
What This Means provides investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.
CEO Connect
CEO Connect allows investors to hear directly from company CEOs, who will provide a brief presentation followed by an interactive Q&A session. Investors and interested parties have the opportunity to submit questions live during the event.
KOL Connect
KOL Connect features a moderated, in-depth discussion with members of the management team from participating companies along with Key Opinion Leaders.
What This Means
Featuring Ernexa Therapeutics
November 6, 2025
Sanjeev Luther, President and CEO of Ernexa, discusses the Company’s recently announced partnership agreement with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.
What This Means
Featuring HCW Biologics
October 22, 2025
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, discusses the Company’s lead product candidate, known as HCW11-040, which is the Company’s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor.
What This Means
Featuring HCW Biologics
September 30, 2025
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics discusses the Company’s recent news announcing its second-generation T-Cell Engager program. The Company has joined a small group of innovative biotechnology companies who have discovered new compounds that overcome resistance mechanisms and improve the ability to treat solid tumors.
What This Means
Featuring enVVeno Medical
September 26, 2025
Rob Berman, CEO discusses the Company’s recent news announcing it filed a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) received on August 19, 2025, in response to its Premarket Approval (PMA) application for the VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).
What This Means
Featuring Nuwellis, Inc.
September 17, 2025
Ryan Marthaler, Vice President of Product Marketing & Business Development of Nuwellis, discussed the Company’s recent news release announcing that the National Institutes of Health (NIH) has awarded an approximately $3 million multi-year grant to its development partner, Koronis Biomedical Technologies Corporation (KBT).
What This Means
Featuring Autonomix
September 4, 2025
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced longer-term post hoc analysis results from its proof-of-concept human clinical trial (“PoC 1”) which demonstrated sustained pain reduction, quality of life gains and 100% zero opioid use.
KOL Connect
Featuring Palisade Bio
August 25, 2025
Moderated discussion with leading expert in Fibrostenotic Crohn’s Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan
Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in the new frontier of IBD therapeutics
What This Means
Featuring Senti Biosciences
August 12, 2025
Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company’s recently announced recommended Phase 2 dose selection for its potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy, SENTI-202, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML).
What This Means
Featuring Sonnet BioTherapeutics
August 11, 2025
Dr. Richard Kenney, Chief Medical Officer of Sonnet discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
What This Means
Featuring enVVeno Medical
August 4, 2025
Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discuss the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval.
What This Means
Featuring GRI Bio
July 31, 2025
Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discusses the Company’s recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (“IPF”).
What This Means
Featuring Akari Therapeutics
July 29, 2025
Abizer Gaslightwala, President and CEO of Akari Therapeutics discusses Akari’s commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1.
CEO Connect
Featuring CNS Pharmaceuticals
July 09, 2025
John Climaco, CEO of CNS Pharmaceuticals provides an overview of CNSP’s lead program, TPI 287, and discusses key insights from his recent attendance at the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, MA.
What This Means
Featuring Akari Therapeutics
June 26, 2025
Abizer Gaslightwala, President and CEO of Akari Therapeutics discusses the Company’s recently issued India Patent No. 562,919 titled, “Thailanstatin Analogs,” covering claims for its potent immuno-oncology PH1 payload, proprietary non-cleavable and cleavable linkers and ADC technology which has applications across various cancer targets.
KOL Connect
Featuring: CNS Pharmaceuticals
June 24, 2025
Dr. Erin Dunbar, a founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, discusses the patient journey and current treatment landscape for Glioblastoma Multiforme and CNS Pharma’s lead product candidate, TPI 287, and its potential as a treatment for GBM as well as for future indications in metastatic tumors.
What This Means
Featuring: Moleculin Biotech
June 18, 2025
Walter Klemp, Founder, President, CEO and Chairman of Moleculin, discussed the Company’s recently announced positive FDA feedback received on the Pediatric Study Plan for Annamycin in children with relapsed/refractory acute myeloid leukemia (R/R AML).
What This Means
Featuring: SENTI Bio
June 18, 2025
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia